← Back to Search

Soluble Guanylate Cyclase Stimulators

Combo Riociguat and Ambrisentan Therapy for Pulmonary Hypertension

Phase 4
Waitlist Available
Led By Naushad Hirani, MD
Research Sponsored by University of Calgary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 and 12 months
Awards & highlights

Study Summary

To evaluate the safety and efficacy of first-line combination therapy using riociguat with ambrisentan in patients with Pulmonary Arterial Hypertension (PAH).

Eligible Conditions
  • Pulmonary Hypertension

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 and 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Pulmonary Vascular resistance
Secondary outcome measures
Clinical worsening
Dyspnea
Echocardiographic parameters
+7 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Combo Riociguat and Ambrisentan TherapyExperimental Treatment1 Intervention
Riociguat Oral Product and Ambrisentan Oral Product to be given in combination to de novo (untreated) patients.

Find a Location

Who is running the clinical trial?

University of CalgaryLead Sponsor
792 Previous Clinical Trials
869,134 Total Patients Enrolled
BayerIndustry Sponsor
2,240 Previous Clinical Trials
25,332,757 Total Patients Enrolled
Naushad Hirani, MDPrincipal InvestigatorUniversity of Calgary
1 Previous Clinical Trials
12 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Upfront Combination Pulmonary Arterial Hypertension Therapy
2016. "Upfront Combination Pulmonary Arterial Hypertension Therapy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03809156.
All > Pulmonary Arterial Hypertension
~2 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top